Stemenhance Research


Stemenhance ResearchWhen I first l
earned about StemEnhance I went looking for research, because let’s face it, when we’re asking the question ‘does StemEnhance really work?‘, being able to read some scientific studies that back up the testimonials of current StemEnhance users helps us to make a decision about whether we try it ourselves.

So this page contains links to research and studies on StemEnhance, plus additional studies or articles about stem cell nutrition that might be of interest. I’ve also quoted from the conclusions on most of the studies for those who don’t have time – or the tenacity – to read the entire novel…

StemEnhance Studies

StemEnhance & Muscle Injury

Mobilization of bone marrow stem cells with StemEnhance® improves muscle regeneration in cardiotoxin-induced muscle injury.

Bone marrow-derived stem cells have the ability to migrate to sites of tissue damage and participate in tissue regeneration. The number of circulating stem cells has been shown to be a key parameter in this process. Therefore, stimulating the mobilization of bone marrow stem cells may accelerate tissue regeneration in various animal models of injury. In this study we investigated the effect of the bone marrow stem cells mobilizer StemEnhance (SE), a water-soluble extract of the cyanophyta Aphanizomenon flos-aquae(AFA), on hematopoietic recovery after myeloablation as well as recovery from cardiotoxin-induced injury of the anterior tibialis muscle in mice. Control and SE-treated female mice were irradiated, and then transplanted with GFP+ bone marrow stem cells and allowed to recover. Immediately after transplant, animals were gavaged daily with 300 mg/kg of SE in PBS or a PBS control. After hematopoietic recovery (23 days), mice were injected with cardiotoxin in the anterior tibialis muscle. Five weeks later, the anterior tibialis muscles were analyzed for incorporation of GFP+ bone marrow-derived cells using fluorescence imaging. SE significantly enhanced recovery from cardiotoxin-injury. However, StemEnhance did not affect the growth of the animal and did not affect hematopoietic recovery after myeloablation, when compared to control. This study suggests that inducing mobilization of stem cells from the bone marrow is a strategy for muscle regeneration.

StemEnhance Studies

StemEnhance & Muscle Injury

Mobilization of bone marrow stem cells with StemEnhance® improves muscle regeneration in cardiotoxin-induced muscle injury.

Bone marrow-derived stem cells have the ability to migrate to sites of tissue damage and participate in tissue regeneration. The number of circulating stem cells has been shown to be a key parameter in this process. Therefore, stimulating the mobilization of bone marrow stem cells may accelerate tissue regeneration in various animal models of injury. In this study we investigated the effect of the bone marrow stem cells mobilizer StemEnhance (SE), a water-soluble extract of the cyanophyta Aphanizomenon flos-aquae(AFA), on hematopoietic recovery after myeloablation as well as recovery from cardiotoxin-induced injury of the anterior tibialis muscle in mice. Control and SE-treated female mice were irradiated, and then transplanted with GFP+ bone marrow stem cells and allowed to recover. Immediately after transplant, animals were gavaged daily with 300 mg/kg of SE in PBS or a PBS control. After hematopoietic recovery (23 days), mice were injected with cardiotoxin in the anterior tibialis muscle. Five weeks later, the anterior tibialis muscles were analyzed for incorporation of GFP+ bone marrow-derived cells using fluorescence imaging. SE significantly enhanced recovery from cardiotoxin-injury. However, StemEnhance did not affect the growth of the animal and did not affect hematopoietic recovery after myeloablation, when compared to control. This study suggests that inducing mobilization of stem cells from the bone marrow is a strategy for muscle regeneration.

StemEnhance: Ankle Study

Use of Stem Cell Mobilizer se2® as Part of Conventional Treatment on Ankle Injuries to Expedite Recovery in Professional Soccer Players

Endogenous Stem Cell Mobilization and more specifically the use of the stem cell mobilizer SE2® therefore emerge as possible complementary protocols to support the effectiveness of conventional treatment for sport ankle injuries, thereby decreasing the recovery time and reducing the critical off match time for the professional soccer player. Further investigations should be done with a broader spectrum of sport injuries.

Note: SE2 was an earlier version of StemEnhance Ultra.

StemEnhance & Diabetes

The Effect of In Vivo Mobilization of Bone Marrow Stem Cells on the Pancreas of Diabetic Albino Rats

In conclusion, StemEnhance successfully mobilized BM stem cells which migrated to diabetic pancreas with subsequent increase in pancreatic islet β cells area.

StemEnhance Toxicity

Subchronic toxicity (90 days) of StemEnhance™ in Wistar rats

Treatment-related morphological abnormalities were not found in any organs/tissues examined. These findings confirm that high-dose subchronic exposure to StemEnhance does not lead to toxicity. The dose of StemEnhance tested in the rat was ∼7 times higher than the maximum label recommended daily dose for human consumption. Therefore, it would appear that no toxicological hazard is likely due to the use of StemEnhance at label doses.

StemEnhance Does Not Promote Tumor Growth

The Stem Cell Mobilizer StemEnhance® Does Not Promote Tumor Growth in an Orthotopic Model of Human Breast Cancer.

Bone marrow-derived stem cells (BMDSC) have been implicated in tumor formation, though it is not clear whether they contribute to tumor growth. A novel mobilizer of BMDSC (StemEnhance®; SE) was used to investigate whether its daily administration promotes tumor growth. Forty mice were surgically transplanted with human MDA-MB-435-GFP breast cancer into the mammary fat pad of nude mice. The mice were gavaged for six weeks with 300 mg/kg of SE. Tumor growth was monitored using live whole-body fluorescence imaging. At the end of the study, tumors were excised and weighed. At the start of the feeding trial, tumor areas for both control and experimental group were statistically identical. Tumor growth rate was slower in the SE group (p=0.014) when compared to the control group. After 6 weeks, tumor areas were 40% larger in the control p<0.01) and mean tumor weight was 35% smaller in the SE-treated group (0.44 g vs. 0.68 g; p=0.031). Feeding of SE did not promote tumor growth but rather reduced the growth of human MDA-MB-435 breast cancer.

Aphanizomenon flos-aquae (AFA) Studies

Inhibitory Effects of AFA Constituents on Human UDP-Glucose Dehydrogenase Activity

Inhibitory effects of Aphanizomenon flos-aquae constituents on human UDP-glucose dehydrogenase activity.

Herein, we show that AFA, and in particular AFA PCB, efficiently inhibits in a dose-dependent manner the activity of human UGDH, a cytosolic enzyme involved both in tumor progression and in phytochemical bioavailability. Our results confirm that the microalgae AFA and its constitutive active principles are natural compounds with high biological activity, as already observed in previous studies on in vitro and in vivo models. Overall, these findings further contribute to better understand the working mechanisms and the potential use of AFA-based food supplements.

 Mobilization of human CD34+CD133+ and CD34+Cd133- stem cells in vivo by consumption of an extract from Alphanizomenon flos-aquae related to modulation of CXCR4 expression by an L-selectin ligand

Mobilization of human CD34+CD133+ and CD34+Cd133- stem cells in vivo by consumption of an extract from Alphanizomenon flos-aquae related to modulation of CXCR4 expression by an L-selectin ligand

Fucoidan Research

Fucoidan ingestion increases the expression of CXCR4 on human CD34þ cells

Fucoidan ingestion increases the expression of CXCR4 on human CD34þ cells

Fucoidan protects mesenchymal stem cells against oxidative stress and enhances vascular regeneration in a murine hindlimb ischemia model

Fucoidan protects mesenchymal stem cells against oxidative stress and enhances vascular regeneration in a murine hindlimb ischemia model.

Taken together, these results show that fucoidan protects MSCs from ischemia-induced cell death by modulation of apoptosis-associated proteins and cellular ROS levels through regulation of the MnSOD and Akt pathways, suggesting that fucoidan could be powerful therapeutic adjuvant for MSC-based therapy in ischemic diseases.

Therapies from Fucoidan; Multifunctional Marine Polymers

Therapies from Fucoidan; Multifunctional Marine Polymers

This review covers some of the more recent research into the bioactivity and discusses potential therapies from fucoidan. The research field has increased in the last decade and has started to produce clinical studies. This review has spanned potential applications as diverse as prion infection and osteoarthritis. The development of fucoidan fractions requires attention to the source and the required characteristics of the fraction, in addition to consideration of the route of delivery. Oral delivery appears promising, with research indicating therapeutic potential in different areas. Increasing bioavailability is likely to be important for orally delivered fucoidan. Overall, the availability and safety of commercially available fucoidan preparations will lead to interesting adjunct and sole therapies for some neglected disease states in addition to providing new approaches to inflammation and fibrosis.

About Stem Cells & Disease

The Role Of Stem Cells In The Body

Understanding the Natural Role of Stem Cells in the Body: A New Understanding of Disease Formation?

The current data does not allow for the precise determination of each organ’s turnover rate, nevertheless this simple observation brings forth a novel understanding of disease formation. While the general understanding is that most degenerative diseases result from the loss of a specific type of cells (pancreatic β-cells for diabetes, dopaminergic neurons in Parkinson’s disease, cone cells in macular degeneration, pneumocytes in the lung, etc.), we can see that a healthy 40 year old adult may have lost and replaced his liver more than 10 times, his pancreas and lung more than 8 times, and yet this person is still healthy without diabetes, liver failure or COPD. Therefore, the loss of cells is not the cause of disease formation; diseases result from a decline in the ability to self-renew which overtime leads to an overall cellular deficit in a tissue. Health is a balance between cellular loss and tissue renewal and diseases develop when the rate of cellular loss exceeds the rate of stem cell-based tissue renewal. This view is supported by a number of recent studies linking the development of various degenerative diseases with a lower number of circulating stem cells. For example, a linear relationship has been documented between the number of circulating stem cells and the various phases of diabetes development, namely impaired fasting glucose, impaired glucose tolerance and insulin-dependent diabetes [21]. Similar observations have been made with cardiovascular diseases [22], atherosclerosis [23], Alzheimer’s disease [24], rheumatoid arthritis [25], pulmonary diseases [26], erectile dysfunction [27], and muscular dystrophy [28]. Therefore, it appears that a decline or failure of endogenous repair might be the underlying cause for the development of various degenerative diseases, and consequently supporting endogenous repair by enhancing stem cell mobilization, circulation and migration into tissues could constitute a novel approach in healthcare.

Stem Cell Therapy For The Heart

Benefits of Stem Cell Therapy for the Heart

As discussed earlier, lack of oxygen in a tissue triggers the release of SDF-1 and VEGF, which leads to the formation of capillaries. As they migrate into the cardiac tissue, stem cells participate in the formation of new blood vessels that restore proper blood flow. In addition, as seen in the brain and other tissues, migration of BMSC to the heart also supports the proliferation of local cardiac stem cells. 3 4 Therefore, a higher number of stem cells in the bloodstream helps maintain optimal cardiovascular health by: 1) providing more stem cells available for migration and differentiation into functional cardiac cells, 2) providing more stem cells for the development of new blood vessels, and 3) providing stem cells which will migrate into the heart and promote the proliferation of local cardiac stem cells.

Therapeutic Potential Of Stimulating Stem Cell Mobilization

 The Therapeutic Potential of Stimulating Endogenous Stem Cell Mobilization

Various stem cell mobilizers have been documented in the scientific literature and many of them have been associated with side effects that prevent the application in humans of what has been documented as effective in various animal models. Such mobilizers include G-CSF, Stem Cell Factor, interleukin-8 and plerixafor (Lemery et al., 2011), which have all been associated with side effects going from diarrhea, nausea, pain and numbness to pericarditis and thrombosis. In spite of the potential benefits, such side effects have largely prevented the use of such compounds for ESCM in humans, and the lack of safe stem cell mobilizers largely explains the limited interest so far in this therapeutic approach. The main challenge in further investigating the therapeutic potential of ESCM remains therefore the development of safe stem cell mobilizers. In the meanwhile, SE appears to be a valuable tool to study the clinical benefits of ESCM.

Stemenhance Research

DISCLAIMER: We do not offer medical advice or claim any of this information will provide you with a cure, treatment or alleviation of any disease or condition. This information is provided to help you gain insight into the potential benefits of increased available adult stem cell numbers. It is not intended as a substitute for professional or medical advice of any kind. You are encouraged to make your own health care decisions based upon your own research and in partnership with your chosen healthcare provider.

ut consectetur mi, sem, ultricies vulputate, ut felis justo venenatis, in dolor